Chris Schott
Stock Analyst at JP Morgan
(3.77)
# 855
Out of 4,479 analysts
60
Total ratings
58.06%
Success rate
5%
Average return
Main Sectors:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,050 → $1,150 | $1,044.66 | +10.08% | 3 | Jun 17, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $850 → $900 | $906.71 | -0.74% | 11 | May 1, 2024 | |
| BIIB Biogen | Maintains: Neutral | $270 → $240 | $228.82 | +4.89% | 2 | Apr 11, 2024 | |
| TEVA Teva Pharmaceutical | Upgrades: Neutral | $14 | $16.55 | -15.41% | 4 | Mar 8, 2024 | |
| PRGO Perrigo Company | Maintains: Overweight | $48 → $41 | $25.99 | +57.75% | 4 | Feb 28, 2024 | |
| RPRX Royalty Pharma | Maintains: Overweight | $45 → $42 | $25.88 | +62.29% | 4 | Feb 20, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $600 → $630 | $477.23 | +32.01% | 5 | Feb 6, 2024 | |
| AMGN Amgen | Reinstates: Neutral | $270 | $310.77 | -13.12% | 1 | Oct 20, 2023 | |
| PFE Pfizer | Maintains: Neutral | $36 → $34 | $27.83 | +22.17% | 3 | Oct 16, 2023 | |
| MRK Merck & Co. | Maintains: Overweight | $120 → $125 | $127.72 | -2.13% | 4 | Feb 23, 2023 | |
| VTRS Viatris | Maintains: Neutral | $13 → $14 | $10.43 | +34.23% | 2 | Nov 15, 2022 | |
| CHRS Coherus BioSciences | Maintains: Neutral | $13 → $11 | $1.39 | +691.37% | 2 | Nov 14, 2022 | |
| ELAN Elanco Animal Health | Maintains: Neutral | $24 → $20 | $14.01 | +42.76% | 3 | Oct 17, 2022 | |
| ZTS Zoetis | Maintains: Overweight | $250 → $225 | $174.81 | +28.71% | 1 | Oct 17, 2022 | |
| GILD Gilead Sciences | Upgrades: Overweight | $72 → $80 | $68.40 | +16.96% | 1 | Oct 4, 2022 | |
| BHC Bausch Health Companies | Downgrades: Neutral | n/a | $7.11 | - | 3 | Jul 29, 2022 | |
| OGN Organon & Co. | Initiates: Neutral | n/a | $20.12 | - | 1 | Jun 15, 2021 | |
| TXMD TherapeuticsMD | Downgrades: Neutral | n/a | $1.66 | - | 1 | May 19, 2020 | |
| KALA Kala Pharmaceuticals | Maintains: Overweight | n/a | $6.71 | - | 2 | Nov 14, 2018 | |
| PCRX Pacira BioSciences | Maintains: Neutral | n/a | $22.74 | - | 2 | Nov 2, 2018 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | n/a | $40.45 | - | 1 | Oct 8, 2018 |
Regeneron Pharmaceuticals
Jun 17, 2024
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,044.66
Upside: +10.08%
Eli Lilly
May 1, 2024
Maintains: Overweight
Price Target: $850 → $900
Current: $906.71
Upside: -0.74%
Biogen
Apr 11, 2024
Maintains: Neutral
Price Target: $270 → $240
Current: $228.82
Upside: +4.89%
Teva Pharmaceutical
Mar 8, 2024
Upgrades: Neutral
Price Target: $14
Current: $16.55
Upside: -15.41%
Perrigo Company
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $25.99
Upside: +57.75%
Royalty Pharma
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $25.88
Upside: +62.29%
IDEXX Laboratories
Feb 6, 2024
Maintains: Overweight
Price Target: $600 → $630
Current: $477.23
Upside: +32.01%
Amgen
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $310.77
Upside: -13.12%
Pfizer
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $27.83
Upside: +22.17%
Merck & Co.
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $127.72
Upside: -2.13%
Viatris
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.43
Upside: +34.23%
Coherus BioSciences
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.39
Upside: +691.37%
Elanco Animal Health
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $14.01
Upside: +42.76%
Zoetis
Oct 17, 2022
Maintains: Overweight
Price Target: $250 → $225
Current: $174.81
Upside: +28.71%
Gilead Sciences
Oct 4, 2022
Upgrades: Overweight
Price Target: $72 → $80
Current: $68.40
Upside: +16.96%
Bausch Health Companies
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.11
Upside: -
Organon & Co.
Jun 15, 2021
Initiates: Neutral
Price Target: n/a
Current: $20.12
Upside: -
TherapeuticsMD
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Kala Pharmaceuticals
Nov 14, 2018
Maintains: Overweight
Price Target: n/a
Current: $6.71
Upside: -
Pacira BioSciences
Nov 2, 2018
Maintains: Neutral
Price Target: n/a
Current: $22.74
Upside: -
Bristol-Myers Squibb Company
Oct 8, 2018
Maintains: Overweight
Price Target: n/a
Current: $40.45
Upside: -